- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06727604
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Central Study Contact
- Phone Number: 18007970414
- Email: clinicaltrials@immunovant.com
Study Locations
-
-
-
Antwerp, Belgium, 2820
- Recruiting
- Site Number - 5303
-
Bruges, Belgium, 80000
- Recruiting
- Site Number - 5301
-
Brussels, Belgium, 1070
- Recruiting
- Site Number - 5302
-
-
-
-
-
Batumi, Georgia, 6000
- Recruiting
- Site Number - 8002
-
Batumi, Georgia, 6010
- Recruiting
- Site Number - 8007
-
Kutaisi, Georgia, 4600
- Recruiting
- Site Number - 8006
-
Marneuli, Georgia, 3000
- Recruiting
- Site Number - 8008
-
Tbilisi, Georgia, 0112
- Recruiting
- Site Number - 8009
-
Tbilisi, Georgia, 0144
- Recruiting
- Site Number - 8004
-
Tbilisi, Georgia, 0144
- Recruiting
- Site Number - 8005
-
Tbilisi, Georgia, 0159
- Recruiting
- Site Number - 8001
-
Tbilisi, Georgia, 0159
- Recruiting
- Site Number - 8003
-
Tbilisi, Georgia, 0159
- Recruiting
- Site Number - 8011
-
Tbilisi, Georgia, 0177
- Recruiting
- Site Number - 8010
-
-
-
-
-
Munich, Germany, 81667
- Recruiting
- Site Number - 6508
-
Munich, Germany, 80336
- Recruiting
- Site Number - 6503
-
Schwerin, Germany, 19049
- Recruiting
- Site Number - 6502
-
Würzburg, Germany, 97080
- Recruiting
- Site Number - 6507
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Recruiting
- Site Number - 6505
-
-
-
-
-
Budapest, Hungary, 1036
- Recruiting
- Site Number - 7554
-
Budapest, Hungary, 1083
- Recruiting
- Site Number - 7556
-
Békéscsaba, Hungary, 5600
- Recruiting
- Site Number - 7558
-
Debrecen, Hungary, 4032
- Recruiting
- Site Number - 7557
-
Pécs, Hungary, 7623
- Recruiting
- Site Number - 7551
-
Szeged, Hungary, 6725
- Recruiting
- Site Number - 7552
-
-
-
-
-
Bologna, Italy, 40138
- Recruiting
- Site Number - 6004
-
Cagliari, Italy, 09124
- Recruiting
- Site Number - 6012
-
Genova, Italy, 16132
- Recruiting
- Site Number - 6011
-
Milan, Italy, 20149
- Recruiting
- Site Number - 6007
-
Milan, Italy, 20122
- Recruiting
- Site Number - 6002
-
Milan, Italy, 20162
- Recruiting
- Site Number - 6009
-
Naples, Italy, 80131
- Recruiting
- Site Number - 6010
-
Pisa, Italy, 56124
- Recruiting
- Site Number - 6003
-
Pisa, Italy, 56126
- Recruiting
- Site Number - 6001
-
Roma, Italy, 00189
- Recruiting
- Site Number - 6005
-
Siena, Italy, 53100
- Recruiting
- Site Number - 6013
-
Varese, Italy, 21100
- Recruiting
- Site Number - 6008
-
-
-
-
-
Gliwice, Poland, 44-102
- Recruiting
- Site Number - 3006
-
Krakow, Poland, 30-074
- Recruiting
- Site Number - 3002
-
Krakow, Poland, 30-688
- Recruiting
- Site Number -3003
-
Lublin, Poland, 20-400
- Recruiting
- Site Number - 3005
-
Lublin, Poland, 91-495
- Recruiting
- Site Number - 3004
-
Lublin, Poland, 20-607
- Recruiting
- Site Number - 3008
-
Poznan, Poland, 60-354
- Recruiting
- Site Number - 3007
-
Warsaw, Poland, 00-0189
- Recruiting
- Site Number - 3001
-
-
-
-
-
San Juan, Puerto Rico, 00907
- Recruiting
- Site Number - 1058
-
San Juan, Puerto Rico, 00921-3313
- Withdrawn
- Site Number - 1037
-
-
-
-
-
Barcelona, Spain, 08036
- Recruiting
- Site Number - 7103
-
Barcelona, Spain, 08035
- Recruiting
- Site Number - 7109
-
Córdoba, Spain, 14004
- Recruiting
- Site Number - 7102
-
Granada, Spain, 18014
- Recruiting
- Site Number - 7106
-
Madrid, Spain, 28006
- Recruiting
- Site Number - 7105
-
Pamplona, Spain, 31008
- Recruiting
- Site Number - 7107
-
Pamplona, Spain, 31008
- Recruiting
- Site Number - 7108
-
Seville, Spain, 41009
- Recruiting
- Site Number - 7101
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Recruiting
- Site Number - 7104
-
-
-
-
-
Cardiff, United Kingdom, CF14 4XW
- Recruiting
- Site Number - 7002
-
Edinburgh, United Kingdom, EH16 4SA
- Recruiting
- Site Number - 7008
-
Huddersfield, United Kingdom, HD3 3EA
- Recruiting
- Site Number - 7005
-
Hull, United Kingdom, HU6 7RX
- Recruiting
- Site Number - 7004
-
London, United Kingdom, SE5 9RS
- Recruiting
- Site Number - 7003
-
Manchester, United Kingdom, M20 4BX
- Recruiting
- Site Number - 7006
-
Newcastle upon Tyne, United Kingdom, NE1 4LP
- Recruiting
- Site Number - 7001
-
Norwich, United Kingdom, NR4 7UY
- Recruiting
- Site Number - 7009
-
Nuneaton, United Kingdom, CV10 7DJ
- Recruiting
- Site Number - 7010
-
-
England
-
Birmingham, England, United Kingdom, B15 2TT
- Recruiting
- Site Number - 7013
-
Bristol, England, United Kingdom, BS10 5NB
- Recruiting
- Site Number - 7012
-
Coventry, England, United Kingdom, CV2 2DX
- Recruiting
- Site Number - 7011
-
London, England, United Kingdom, NW1 2PG
- Recruiting
- Site Number - 7007
-
-
London
-
Cambridge, London, United Kingdom, CB2 0QQ
- Recruiting
- Site Number - 7014
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85015
- Recruiting
- Site Number - 1036
-
Phoenix, Arizona, United States, 85006
- Withdrawn
- Site Number - 1032
-
-
California
-
Huntington Beach, California, United States, 92647
- Recruiting
- Site Number - 1061
-
Los Angeles, California, United States, 90033
- Recruiting
- Site Number - 1001
-
Los Angeles, California, United States, 90095
- Recruiting
- Site Number - 1047
-
Orange, California, United States, 92868
- Recruiting
- Site Number - 1062
-
Sacramento, California, United States, 95816
- Recruiting
- Site Number - 1046
-
San Francisco, California, United States, 94143
- Recruiting
- Site Number - 1034
-
Santa Clarita, California, United States, 91321
- Withdrawn
- Site Number - 1035
-
Torrance, California, United States, 90502
- Recruiting
- Site Number - 1005
-
Walnut Creek, California, United States, 94598
- Withdrawn
- Site Number - 1006
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Recruiting
- Site Number - 1013
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Recruiting
- Site Number - 1010
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20010
- Recruiting
- Site Number - 1040
-
-
Florida
-
Clearwater, Florida, United States, 33756
- Recruiting
- Site Number - 1029
-
Jacksonville, Florida, United States, 32204-1177
- Recruiting
- Site Number - 1055
-
Jacksonville, Florida, United States, 32216
- Recruiting
- Site Number - 1056
-
Miami, Florida, United States, 33136
- Recruiting
- Site Number - 1028
-
Miami, Florida, United States, 33186
- Recruiting
- Site Number - 1065
-
Ocoee, Florida, United States, 34761
- Recruiting
- Site Number - 1064
-
Orlando, Florida, United States, 32819
- Recruiting
- Site Number - 1011
-
Port Charlotte, Florida, United States, 33952
- Recruiting
- Site Number - 1016
-
West Palm Beach, Florida, United States, 33401
- Recruiting
- Site Number - 1012
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Recruiting
- Site Number - 1038
-
Macon, Georgia, United States, 31210
- Recruiting
- Site Number - 1053
-
Stockbridge, Georgia, United States, 30281
- Recruiting
- Site Number - 1020
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Site Number - 1027
-
-
Kansas
-
Kansas City, Kansas, United States, 66210
- Recruiting
- Site Number - 1041
-
-
Kentucky
-
Bowling Green, Kentucky, United States, 42101
- Recruiting
- Site Number - 1045
-
Florence, Kentucky, United States, 41042
- Recruiting
- Site Number - 1054
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Recruiting
- Site Number - 1063
-
New Orleans, Louisiana, United States, 70112
- Recruiting
- Site Number - 1022
-
Shreveport, Louisiana, United States, 71103
- Recruiting
- Site Number - 1048
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Site Number - 1023
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Site Number - 1026
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Recruiting
- Site Number - 1018
-
Flint, Michigan, United States, 48532
- Recruiting
- Site Number - 1069
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Site Number - 1008
-
-
Mississippi
-
Gulfport, Mississippi, United States, 39501
- Recruiting
- Site Number - 1068
-
-
Nebraska
-
Omaha, Nebraska, United States, 68105
- Recruiting
- Site Number - 1017
-
-
Nevada
-
Las Vegas, Nevada, United States, 89148
- Recruiting
- Site Number - 1007
-
-
New York
-
Monroe, New York, United States, 10950
- Recruiting
- Site Number - 1050
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Recruiting
- Site Number - 1051
-
Wilmington, North Carolina, United States, 28401
- Recruiting
- Site Number - 1060
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Site Number - 1057
-
-
Oregon
-
Portland, Oregon, United States, 97035
- Recruiting
- Site Number - 1003
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Withdrawn
- Site Number - 1033
-
Pottstown, Pennsylvania, United States, 19464
- Recruiting
- Site Number - 1043
-
-
South Carolina
-
Summerville, South Carolina, United States, 29485
- Recruiting
- Site Number - 1015
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- Recruiting
- Site Number - 1042
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Site Number - 1066
-
Nashville, Tennessee, United States, 37212
- Recruiting
- Site Number - 1049
-
-
Texas
-
Austin, Texas, United States, 78731
- Recruiting
- Site Number - 1002
-
Bellaire, Texas, United States, 77401
- Recruiting
- Site Number - 1067
-
Dallas, Texas, United States, 75208
- Recruiting
- Site Number - 1019
-
Dallas, Texas, United States, 75231
- Withdrawn
- Site Number - 1031
-
Houston, Texas, United States, 77095
- Withdrawn
- Site Number - 1025
-
Houston, Texas, United States, 77089
- Recruiting
- Site Number - 1071
-
Mesquite, Texas, United States, 75149
- Recruiting
- Site Number - 1004
-
Round Rock, Texas, United States, 78681
- Recruiting
- Site Number - 1009
-
San Antonio, Texas, United States, 78215
- Recruiting
- Site Number - 1014
-
San Antonio, Texas, United States, 78240
- Recruiting
- Site Number - 1052
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Recruiting
- Site Number - 1030
-
Sandy City, Utah, United States, 84093
- Recruiting
- Site Number - 1070
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
- Male or female participants aged ≥ 18 years.
- Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.
- Other, more specific inclusion criteria are defined in the protocol.
Exclusion Criteria:
- Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.
- Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.
- Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation.
- Additional exclusion criteria are defined in the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 1 Period 1 and 2: IMVT-1402
|
600 mg SC QW for 52 weeks
600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
|
|
Experimental: Group 2 Period 1 and 2: IMVT-1402
|
600 mg SC QW for 52 weeks
600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
|
|
Experimental: Group 2 Period 1: IMVT-1402 and Period 2: Placebo
|
600 mg SC QW for 52 weeks
600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
|
|
Placebo Comparator: Group 3 Period 1 and 2: Placebo
|
SC QW for 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26
Time Frame: Week 26
|
Week 26
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of participants who are euthyroid and off ATD at Week 52
Time Frame: Week 52
|
Week 52
|
|
Percentage of participants who are euthyroid, off ATD, and seronegative for TRAb at Week 52
Time Frame: Week 52
|
Week 52
|
|
Percentage of participants who are euthyroid and off ATD at Week 52 and remain euthyroid, off IMVT-1402, and off ATD for 6 months from Week 52 to Week 78
Time Frame: Week 78
|
Week 78
|
|
Percentage of participants who are euthyroid and off ATD at Week 52 and remain euthyroid, off IMVT-1402, and off ATD for 12 months from Week 52 to Week 104
Time Frame: Week 104
|
Week 104
|
|
Percentage of participants who have a TRAb value a specified amount and are euthyroid and off ATD at Week 26 and remain euthyroid, off IMVT-1402, and off ATD for 6 months from Week 26 to Week 52
Time Frame: Week 52
|
Week 52
|
|
Percentage of participants who have a TRAb value a specific amount and are euthyroid and off ATD at Week 26 and remain euthyroid, off IMVT-1402, and off ATD for 12 months from Week 26 to Week 78
Time Frame: Week 78
|
Week 78
|
|
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN at Week 2 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline
Time Frame: Week 2
|
Week 2
|
|
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN at Week 4 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline
Time Frame: Week 4
|
Week 4
|
|
Percentage of participants who are euthyroid, off ATD, and seronegative for TRAb at Week 26
Time Frame: Week 26
|
Week 26
|
|
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN and are off ATD at Week 26
Time Frame: Week 26
|
Week 26
|
|
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN and are off ATD at Week 52
Time Frame: Week 52
|
Week 52
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMVT-1402-2502
- 2024-516020-33-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graves' Disease
-
First Hospital of China Medical UniversityRecruitingGraves´ DiseaseChina
-
The University of Hong KongCompletedRrelapsed Graves' DiseaseHong Kong
-
Seoul National University Bundang HospitalActive, not recruitingGraves' Disease in Remission (Disorder)Korea, Republic of
-
Odense University HospitalCompletedThyroid Associated Ophthalmopathy | Graves´ DiseaseDenmark
-
Northwell HealthRecruitingGraves Disease | Hyperthyroidism | Graves' DiseaseUnited States
-
Immunovant Sciences GmbHEnrolling by invitationGraves' DiseaseUnited States
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Mikael LantzCompleted
-
The University of Hong KongActive, not recruitingThyroid; Functional Disturbance | Relapsed Graves' Disease | Radiofrequency Ablation TreatmentHong Kong
-
Betul UnerRecruitingGraves Disease (Basedow's Disease)Turkey (Türkiye)
Clinical Trials on IMVT-1402
-
Immunovant Sciences GmbHEnrolling by invitationGraves' DiseaseUnited States
-
Immunovant Sciences GmbHRecruitingPrimary Sjögren's SyndromeUnited States, Germany, Poland, Argentina, Brazil, Chile, Colombia, Italy, Mexico, Peru, Canada, Hungary, Romania, Spain, United Kingdom, Greece
-
Immunovant Sciences GmbHActive, not recruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusSerbia, United States, Argentina, Bulgaria, Canada, Chile, Georgia, Germany, Greece, Poland, Puerto Rico, Spain, United Kingdom
-
Immunovant Sciences GmbHRecruitingGeneralized Myasthenia GravisSerbia, United States, Georgia, Germany, Hungary, Romania, Czechia, Denmark, Italy, Spain, United Kingdom, Greece, Poland, Argentina
-
Immunovant Sciences GmbHActive, not recruitingRheumatoid ArthritisUnited States, Argentina, Bulgaria, Czechia, Georgia, Germany, Hungary, Poland, Romania, Spain, United Kingdom
-
Immunovant Sciences GmbHRecruitingGraves' DiseaseUnited States, Georgia, Australia, United Kingdom, Bulgaria, Czechia, Greece, Israel, Latvia, New Zealand, Poland, South Korea, Netherlands, Italy, Brazil, Japan
-
Immunovant Sciences GmbHCompletedGraves DiseaseGermany
-
Immunovant Sciences GmbHCompletedThyroid Eye DiseaseUnited States, Canada, Georgia, Germany, Israel, Italy, Japan, Poland, United Kingdom
-
Immunovant Sciences GmbHEnrolling by invitationChronic Inflammatory Demyelinating PolyneuropathyUnited States, Brazil, Italy, Serbia, Slovakia, Argentina, Belgium, Germany, Greece, Poland, Romania
-
NVP HealthcareCompleted